Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes (JACC October 2022-1)

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes (JACC October 2022-1) is organized by American College of Cardiology (ACC).,Date of Release: September 26, 2022,Term of Approval/Date of CME/MOC/ECME Expiration: September 25, 2023,Description:,This study sought to assess whether low-dose aspirin benefits individuals with elevated plasma lipoprotein(a)-associated genotypes in the setting of primary prevention.